The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.
 
Susan Michelle Geyer
Research Funding - Bristol-Myers Squibb (Inst)
 
Michelle R. Mahoney
No Relationships to Disclose
 
Timothy R. Asmis
Honoraria - Ipsen
Consulting or Advisory Role - Bayer; Celgene; Eisai; Ipsen; SERVIER
Research Funding - Bristol Myers Squibb Foundation (Inst); Deciphera (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Nathan Hall
No Relationships to Disclose
 
Sanja Karovic
No Relationships to Disclose
 
Michael V. Knopp
No Relationships to Disclose
 
Priya Kumthekar
Stock and Other Ownership Interests - Vivacitas Oncology
Consulting or Advisory Role - Biocept; Biocept; ElevateBio; Janssen; Novocure; Orbus Therapeutics
Research Funding - Angiochem; DNAtrix; Genentech; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Andrew B. Nixon
Consulting or Advisory Role - GlaxoSmithKline; Kanghong Pharma; Leap Therapeutics; Lilly; Promega
Research Funding - AstraZeneca/MedImmune (Inst); Eureka Therapeutics (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Leadiant Biosciences (Inst); medpacto (Inst); OncoMed (Inst); Promega (Inst); Seagen (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Gilead Sciences (I); Incyte (I); Ipsen (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); MabVax (Inst); Roche (Inst); Silenseed (Inst)
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
Jonathan R. Strosberg
Consulting or Advisory Role - Novartis
Speakers' Bureau - Ipsen; Lexicon
Research Funding - Novartis
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Taiho Pharmaceutical
Consulting or Advisory Role - Array BioPharma
Research Funding - Boston Biomedical (Inst)
 
Michael L. Maitland
Consulting or Advisory Role - Acceleron Pharma (I); Actelion/Janssen (I); Gossamer Bio (I); Reata Pharmaceuticals (I); United Therapeutics (I)
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
 
Emily K. Bergsland
Leadership - More Health (I)
Stock and Other Ownership Interests - More Health (I)
Honoraria - UpToDate
Consulting or Advisory Role - Advanced Accelerator Applications; Crinetics Pharmaceuticals; Hutchison MediPharma; more health (I)
Research Funding - Merck; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Crinetics Pharmaceuticals